News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
《大行》中金升藥明生物(02269.HK)目標價至48元 維持「跑贏行業」評級
中金發表報告指，藥明生物(02269.HK)2025年業績高於該行預期，收入217.9億元人民幣，按年增長16.7%；淨利潤49.1億元人民幣，按年堵長46.3%；經調整淨利潤56.4億人民幣，按年增長17.9%。業績超該行預期，盈利能力增強主要因高利潤率業務佔比提升、產能利用率提高，以及營運效率提升。公司指引2026年收入將實現13-17%按年增長(考慮匯...
Reset
Send
The window will close in 5 seconds
《大行》中金升藥明生物(02269.HK)目標價至48元 維持「跑贏行業」評級
Close
Recommend
5
Positive
7
Negative
0
 
SHORT SELL
 
STOCK INFO
aacat by AASTOCKS
Open a new trading account to get TENCENT shares!

中金發表報告指，藥明生物(02269.HK)  -1.600 (-4.828%)    Short selling $240.24M; Ratio 17.853%   2025年業績高於該行預期，收入217.9億元人民幣，按年增長16.7%；淨利潤49.1億元人民幣，按年堵長46.3%；經調整淨利潤56.4億人民幣，按年增長17.9%。

業績超該行預期，盈利能力增強主要因高利潤率業務佔比提升、產能利用率提高，以及營運效率提升。公司指引2026年收入將實現13-17%按年增長(考慮匯率影響)。

考慮到公司經營效率提升，該行上調藥明生物2026年及2027年經調整淨利潤6.3%及9.7%，各至62.1億及71.9億人民幣，維持「跑贏行業」評級，上調目標價6.7%至48港元。(ha/w)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-03-26 16:25.)

Switch to Auto-Translated Version
AASTOCKS新聞
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.